Description General description A potent, cell-permeable, and reversible metabolically-stable cAMP antagonist that inhibits cAMP-dependent protein kinase and shows preference for PKA type I. More lipophilic than cAMP antagonist Rp-cAMPS (Cat. No. 116814). Cell-permeable, potent, reversible, and metabolically stable antagonist of cAMP that is resistant to the action of mammalian cyclic nucleotide phosphodiesterases. Rp-8-Br-cAMPS is more lipophilic as compared to 8-Br-cAMP and Rp-cAMPS. In contrast to other common ATP-site inhibitors or to its parent compound Rp-cAMPS, Rp-8-Br-cAMPS discriminates between both isozymes of protein kinase A, preferring type I, thus providing additional selectivity. By occupying cAMP binding sites, prevents dissociation and activation of the kinase holoenzyme. λ = 264 nm (H2O, pH 7.0); εmax 17,000 M-1cm-1. Note: 5 µmol = 2.23 mg. Packaging 5 μmol in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target PKA 1 Product does not compete with ATP. Reversible: yes Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Calaghan, S.C., et al. 1999. Pflugers Arch. 437, 780. Gjertsen, B.T., et al. 1995. J. Biol. Chem. 270, 20599. Yokozaki, H., et al. 1992. Cancer Res.52, 2504. Dostmann, W.R. et al. 1990. J. Biol. Chem.265, 10484. Legal Information Sold under license of Patent DE 3,802,865.4 issued to BIOLOG LSI.